Could a diabetes drug sharpen your mind?
NCT ID NCT04466345
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether semaglutide, a drug used for diabetes, can improve cognitive function in people with major depressive disorder. 72 overweight adults with below-average thinking speed took either semaglutide or a placebo for 16 weeks. Researchers measured changes in executive function, memory, and attention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide
- What this could lead to
- If it works, this could point toward a new way to help with thinking and memory problems in people with depression.
- What could go wrong
- This is a small, early-phase study. The results may not apply to everyone, and semaglutide can cause side effects like nausea or stomach issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway ease teen depression?
- Can a nasal spray break through tough depression?
- Could a new drug offer hope for Treatment-Resistant depression?
- Targeting depression: can MRI-Guided brain zaps rewire key circuits?
- Can a psychedelic trip plus a gentle ear zap lift depression?
- Can a smart brain implant outsmart depression?